

DEVA API PRODUCT LIST

| Product name | Pharmaceutical Group | DMF Holder | DMF / CEP / Pharmacopoeias |
|---|---|---------------|--|
| Fingolimod Hydrochloride | Antineoplastic and Immunomodulating Agents | DEVA | DEVA EU DMF (AP+RP) available. 3.2.S: approved in EU (NL, DE); CEP: application done. |
| Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | DEVA | R0-CEP 2016-299-Rev 00 DEVA EU DMF (AP+RP) and CEP available. |
| Lenalidomide | Antineoplastic and Immunomodulating Agents | DEVA | DEVA EU-DMF (AP+RP): approved in EU (NL, DE) |
| Sildenafil Citrate | Genito Urinary System and Sex Hormones | DEVA | NA |
| Pomalidomide | Antineoplastic and Immunomodulating Agents | DEVA | AP-DMF: available EU-DMF (AP+RP): under preparation |
| Indacaterol Maleate | Respiratory System | DEVA | AP-DMF: available EU-DMF (AP+RP): under preparation |
| Tiotropium Bromide Anhydrous | Respiratory System | DEVA | AP-DMF: available EU-DMF (AP+RP): can be prepared in case of demand If required, in case of demand, we can produce and have the capacity for monohydrate form. |
| Teriflunomide | Antineoplastic and Immunomodulating Agents | DEVA | AP-DMF: available EU-DMF (AP+RP): under preparation Published in Pharm. Europe Following |
| Dasatinib | Antineoplastic and Immunomodulating Agents | DEVA | AP-DMF: available EU-DMF (AP+RP): under preparation |
| Isoproterenol Hydrochloride | Respiratory System | DEVA | EP, USP; CEP: application is not planned. |
| Nilotinib Hydrochloride Dihydrate | Antineoplastic and Immunomodulating Agents | DEVA | EP describes monohydrate. Therefore, we cannot apply for CEP. |
| Nilotinib Dihydrochloride Dihydrate | Antineoplastic and Immunomodulating Agents | DEVA | EP describes monohydrate. Therefore, we cannot apply for CEP. |

NA: Not Applicable.







